Hormonal
Central administration of ghrelin directly regulates adipocyte metabolism by increasing glucose utilization and promoting fat storage in white adipose tissue (WAT) while decreasing thermogenesis in brown adipose tissue (BAT), independent of increased food intake.
This research suggests that the hormone ghrelin, when acting on the brain, directly tells fat cells to store more fat and burn less energy, independent of how much you eat. This implies that hormonal signals play a critical role in fat storage efficiency, potentially making weight management harder when ghrelin levels are chronically elevated, regardless of caloric intake.
We demonstrate here that central ghrelin increased food intake and independently regulated adipocyte metabolism. In white adipocytes it favored glucose and triglyceride (TG) uptake, increased lipogenesis, and inhibited lipid oxidation. In brown adipocytes icv ghrelin decreased the expression of uncoupling proteins (UCPs), which usually contribute to energy dissipation.
Why this rating
High-quality animal study with rigorous controls (pair-feeding, knockout models) demonstrating dose-dependence and mechanism specificity.
Source
Ghrelin action in the brain controls adipocyte metabolism
C. Theander-Carrillo · Journal of Clinical Investigation · 2006
DOI 10.1172/jci25811
More from this paper
- The metabolic effects of central ghrelin on adipose tissue are mediated by the sympathetic nervous system, as evidenced by the lack of metabolic response in mice lacking beta-adrenergic receptors.Good
- Endogenous ghrelin is physiologically relevant for regulating lipid-metabolizing enzymes in white adipose tissue, as ghrelin-deficient mice exhibit decreased expression of fat-storage enzymes (LPL, SCD1).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →